AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35506190 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mango consumption, dosage not specified, duration not specified
Number of subjects: 0
Study 35506244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of serrated polyps
Number of subjects: 2102
Study 35506244 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 2102
Study 35506244 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and smoking exposure
Number of subjects: 2102
Study 35506349 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural History cohort (ALGS NH)
Number of subjects: 59
Study 35506389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (various types, doses, and combinations)
Number of subjects: 10303
Study 35507014 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide-based neoadjuvant therapy
Number of subjects: 211
Study 35507146 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with T1DM
Number of subjects: 70
Study 35507146 — intervention group
Group type: COMPARATOR
Intervention: Controls without T1DM
Number of subjects: 70
Study 35507355 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 2-dose SARS-CoV-2 vaccination regimen
Number of subjects: 1505
Study 35507355 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of SARS-CoV-2 vaccine
Number of subjects: 1505
Study 35507396 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS intervention in treatment practices
Number of subjects: 2423
Study 35507396 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS intervention in treatment practices (subgroup analysis)
Number of subjects: 2423
Study 35507396 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 2423
Study 35507403 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care + circuit-based resistance training exercise group
Number of subjects: 38
Study 35507403 — intervention group
Group type: COMPARATOR
Intervention: Standard of care waitlist control group
Number of subjects: 38
Study 35507406 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer conception intervention (Sinikithemba Kwabesilisa) with 3 counseling and 2 booster sessions over 12 weeks, promoting ART uptake and adherence, HIV serostatus disclosure, and safer conception strategies.
Number of subjects: 16
Study 35507536 — intervention group
Group type: EXPERIMENTAL
Intervention: BOXR1030 (GPC3-targeted CAR T cell co-expressing GOT2)
Number of subjects: 0
Study 35507536 — intervention group
Group type: COMPARATOR
Intervention: Control GPC3 CAR alone
Number of subjects: 0
Study 35507606 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir-cobicistat
Number of subjects: 400
Study 35507606 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-ritonavir
Number of subjects: 400
Study 35507739 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat 266 μg/kg orally, once daily, from baseline to Week 72, with twice-daily dosing permitted from Week 72.
Number of subjects: 33
Study 35507739 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat
Number of subjects: 33
Study 35507774 — intervention group
Group type: EXPERIMENTAL
Intervention: MUSTCOOL cooling intervention
Number of subjects: 140
Study 35507774 — intervention group
Group type: COMPARATOR
Intervention: Placebo cooling patch intervention
Number of subjects: 140
Study 35507774 — intervention group
Group type: EXPERIMENTAL
Intervention: MUSTCOOL cooling intervention for DFU
Number of subjects: 140
Study 35507774 — intervention group
Group type: COMPARATOR
Intervention: Placebo cooling patch intervention for DFU
Number of subjects: 140
Study 35507946 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-Free Omega-3 Fatty Acid Eye Drop
Number of subjects: 0
Study 35507993 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovations in logistics and coordination of activities
Number of subjects: 1105
Study 35508003 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive plantar flexor stretching for 120 seconds
Number of subjects: 24
Study 35508341 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on elder abuse (full-day education including theory, group discussions, forum theatre, and post-training reflection)
Number of subjects: 750
Study 35508346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab induction dose
Number of subjects: 140
Study 35508390 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitoring
Number of subjects: 587
Study 35508390 — intervention group
Group type: COMPARATOR
Intervention: Non-monitored patients
Number of subjects: 587
Study 35508515 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection at M3
Number of subjects: 1062
Study 35508515 — intervention group
Group type: EXPERIMENTAL
Intervention: Working department specialty
Number of subjects: 1062
Study 35508515 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1062
Study 35508515 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, professional category, years of experience, public transportation use
Number of subjects: 1062
Study 35508559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Down and Play intervention during routine immunization visits
Number of subjects: 53
Study 35508559 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 53
Study 35508986 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV every 8 weeks (Q8W)
Number of subjects: 918
Study 35508986 — intervention group
Group type: COMPARATOR
Intervention: Daily oral standard of care (SoC)
Number of subjects: 918
Study 35508986 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV Q8W
Number of subjects: 918
Study 35508986 — intervention group
Group type: COMPARATOR
Intervention: Daily oral SoC
Number of subjects: 918
Study 35509022 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically controlled capsule endoscopy (MCE)
Number of subjects: 768
Study 35509022 — intervention group
Group type: COMPARATOR
Intervention: Magnetically controlled capsule endoscopy (MCE) with magnetic steering
Number of subjects: 768
Study 35509030 — intervention group
Group type: EXPERIMENTAL
Intervention: Withing Steel HR activity tracker for 12 months
Number of subjects: 300
Study 35509435 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-sensing robotic-assisted bronchoscopy (SSRAB) combined with portable 3D imaging
Number of subjects: 30
Study 35510128 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI4% ≥5 episodes/hour
Number of subjects: 1072
Study 35510128 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI4% ≥10 episodes/hour
Number of subjects: 1072
Study 35510128 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI4% ≥15 episodes/hour
Number of subjects: 1072
Study 35510128 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI4%
Number of subjects: 1072
Study 35510546 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-CS
Number of subjects: 520
Study 35510546 — intervention group
Group type: COMPARATOR
Intervention: AMI-CS
Number of subjects: 520
Study 35510546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 520
Study 35510547 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment added to traditional HIV risk reduction education
Number of subjects: 542
Study 35510547 — intervention group
Group type: COMPARATOR
Intervention: Traditional HIV risk reduction education
Number of subjects: 542
Study 35510711 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment (e.g., low-molecular-weight heparin)
Number of subjects: 206
Study 35510711 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation treatment
Number of subjects: 206
Study 35510813 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-stroke socioeconomic status (SES)
Number of subjects: 176
Study 35511120 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine with soft multifocal contact lenses (SMCLs)
Number of subjects: 138
Study 35511120 — intervention group
Group type: COMPARATOR
Intervention: soft multifocal contact lenses (SMCLs) alone
Number of subjects: 138
Study 35511120 — intervention group
Group type: COMPARATOR
Intervention: single-vision contact lenses
Number of subjects: 138
Study 35511148 — intervention group
Group type: EXPERIMENTAL
Intervention: MRG003 (0.1 to 2.5 mg/kg administered every 3 weeks during phase 1a; recommended dose of 2.5 mg/kg during phase 1b)
Number of subjects: 61
Study 35511148 — intervention group
Group type: EXPERIMENTAL
Intervention: MRG003
Number of subjects: 61
Study 35511170 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 505
Study 35511170 — intervention group
Group type: COMPARATOR
Intervention: Appropriate medical therapy
Number of subjects: 505
Study 35511225 — intervention group
Group type: EXPERIMENTAL
Intervention: TAKE IT intervention (multifaceted adherence monitoring strategy)
Number of subjects: 449
Study 35511229 — intervention group
Group type: EXPERIMENTAL
Intervention: ElderTree on a smart display along with usual care
Number of subjects: 291
Study 35511229 — intervention group
Group type: EXPERIMENTAL
Intervention: ElderTree on a touch screen laptop along with usual care
Number of subjects: 291
Study 35511229 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 291
Study 35511286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 709
Study 35511527 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Inventory of Problems (SIP-2R)
Number of subjects: 0
Study 35511527 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigroup confirmatory factor analysis (MGCFA) model comprising one general alcohol-related harm factor
Number of subjects: 0
Study 35511740 — intervention group
Group type: EXPERIMENTAL
Intervention: IMGC936 (a next-generation maytansinoid-based antibody-drug conjugate)
Number of subjects: 0
Study 35511740 — intervention group
Group type: EXPERIMENTAL
Intervention: IMGC936
Number of subjects: 0
Study 35511761 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysine (AZLI; Cayston®) for 4 weeks
Number of subjects: 18
Study 35511917 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control arms from four NSCLC RCTs (IMpower150-WT, IMpower130-WT, IMpower131, IMpower132)
Number of subjects: 0
Study 35511917 — intervention group
Group type: COMPARATOR
Intervention: Real-world data (RWD) external controls
Number of subjects: 0
Study 35511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Number of subjects: 0
Study 35511920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Number of subjects: 0
Study 35511920 — intervention group
Group type: COMPARATOR
Intervention: Mucosally vaccinated, SARS-CoV-2-infected hamsters
Number of subjects: 0
Study 35512229 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived frailty (subjective assessment by physicians)
Number of subjects: 13621
Study 35512229 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective frailty (Modified Frailty Index)
Number of subjects: 13621
Study 35512229 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-recommended edoxaban dose regimens
Number of subjects: 13621
Study 35512229 — intervention group
Group type: COMPARATOR
Intervention: Comparison of perceived frailty vs. objective frailty
Number of subjects: 13621
Study 35512369 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet (PBD)
Number of subjects: 18
Study 35512369 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 18
Study 35512742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) using a low-energy X-ray source (50 kV, Intrabeam, Carl Zeiss) with 10 Gy prescribed at a 5-mm depth from the tumor bed.
Number of subjects: 41
Study 35512742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with adjuvant gemcitabine-based chemotherapy administered 8-12 weeks after surgery.
Number of subjects: 41
Study 35512743 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment with VerifyNow assay results
Number of subjects: 13160
Study 35512743 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype analysis
Number of subjects: 13160
Study 35512761 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 73
Study 35513751 — intervention group
Group type: EXPERIMENTAL
Intervention: One occurrence of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Number of subjects: 1000
Study 35513751 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more occurrences of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Number of subjects: 1000
Study 35513779 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 6615
Study 35513779 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 6615
Study 35513807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid learning environment
Number of subjects: 376
Study 35513807 — intervention group
Group type: COMPARATOR
Intervention: Distance learning environment
Number of subjects: 376
Study 35513826 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose of LMWH (> 100 IU/kg/day)
Number of subjects: 5870
Study 35513826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of LMWH (≤ 100 IU/kg/day)
Number of subjects: 5870
Study 35513826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of LMWH
Number of subjects: 5870
Study 35513826 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 5870
Study 35513832 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with capecitabine and oxaliplatin
Number of subjects: 30
Study 35513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immune-inflammatory scores (PLR, lymphocyte count, PNI)
Number of subjects: 312
Study 35513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immune-inflammatory scores (NLR, PLR, LMR, PNI, SII)
Number of subjects: 312
Study 35513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lymphocyte count
Number of subjects: 312
Study 35513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PLR
Number of subjects: 312
Study 35513845 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PNI
Number of subjects: 312
Study 35514021 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection of overweight through primary health care contacts (including dental care)
Number of subjects: 992
Study 35514021 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examination after approximately one year
Number of subjects: 992
Study 35514021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk markers in school children with overweight
Number of subjects: 992
Study 35514111 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-based attendance strategy (daily rapid antigen testing, stay at work if negative)
Number of subjects: 24027
Study 35514111 — intervention group
Group type: COMPARATOR
Intervention: Standard 10-day self-isolation
Number of subjects: 24027
Study 35514131 — intervention group
Group type: COMPARATOR
Intervention: Educational interventions for health professionals
Number of subjects: 4936
Study 35514201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (1200 mg IV on Day 1, additional doses of 1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18)
Number of subjects: 8
Study 35514201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 8
Study 35514770 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil inhalation powder (TreT)
Number of subjects: 51
Study 35514770 — intervention group
Group type: COMPARATOR
Intervention: Treprostinil inhalation solution
Number of subjects: 51
Study 35516461 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT) delivering 66-69 Gy and 73.5 Gy in 30 fractions to the whole prostatic fossa and to the local failure(s) seen at DCE-MRI
Number of subjects: 62
Study 35516461 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT)
Number of subjects: 62
Study 35517914 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-358 (0.3-28.0 μg/kg in SAD; 3-24.0 μg/kg in MAD)
Number of subjects: 112
Study 35517914 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-358
Number of subjects: 112
Study 35517914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 35518121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating capsule (VC), two capsules per week for six weeks
Number of subjects: 107
Study 35518121 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 107
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated aldosterone-renin ratio
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline loading test
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics and elevated aldosterone-renin ratio
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of primary aldosteronism
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in cardioembolic stroke
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in resistant hypertension
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in hypertension and atrial fibrillation
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for primary aldosteronism
Number of subjects: 300
Study 35518929 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree for screening
Number of subjects: 300
Study 35521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736) with Tremelimumab in combination with image-guided stereotactic body radiotherapy
Number of subjects: 0
Study 35521657 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35521767 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum LH/FSH ratios
Number of subjects: 236
Study 35521767 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH/FSH ratios
Number of subjects: 236
Study 35522297 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 89
Study 35522297 — intervention group
Group type: COMPARATOR
Intervention: ICGA (Indocyanine Green Angiography)
Number of subjects: 89
Study 35522459 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet intervention for prolonged grief symptoms
Number of subjects: 100
Study 35522464 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleprehabilitation (multimodal virtual prehabilitation services)
Number of subjects: 100
Study 35522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook weight loss group with open enrollment
Number of subjects: 68
Study 35522466 — intervention group
Group type: COMPARATOR
Intervention: Facebook weight loss group with closed enrollment
Number of subjects: 68
Study 35522941 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1/TIGIT bispecific antibody
Number of subjects: 0
Study 35522969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria for chronic lung allograft dysfunction (CLAD)
Number of subjects: 166
Study 35522969 — intervention group
Group type: COMPARATOR
Intervention: NIH criteria for bronchiolitis obliterans syndrome (BOS)
Number of subjects: 166
Study 35523118 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin administered IV
Number of subjects: 75
Study 35523519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest GDP/capita countries
Number of subjects: 439
Study 35523519 — intervention group
Group type: COMPARATOR
Intervention: Middle GDP/capita countries
Number of subjects: 439
Study 35523519 — intervention group
Group type: COMPARATOR
Intervention: High GDP/capita countries
Number of subjects: 439
Study 35523519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 439
Study 35523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated CAP ipsilateral to acute ischemic anterior circulation stroke (icCAP)
Number of subjects: 196
Study 35523659 — intervention group
Group type: COMPARATOR
Intervention: No icCAP
Number of subjects: 196
Study 35523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated CAP ipsilateral to acute ischemic anterior circulation stroke (icCAP) in patients with cryptogenic stroke
Number of subjects: 196
Study 35523659 — intervention group
Group type: COMPARATOR
Intervention: No icCAP in patients with cryptogenic stroke
Number of subjects: 196
Study 35523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured fibrous cap
Number of subjects: 196
Study 35523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage
Number of subjects: 196
Study 35523696 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-to-date care for T2DM
Number of subjects: 73484
Study 35523821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 10 weeks
Number of subjects: 12
Study 35524015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific PEEK implant
Number of subjects: 8
Study 35524068 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 11616
Study 35524068 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 11616
Study 35524223 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infected CKD patients
Number of subjects: 0
Study 35524223 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of patients
Number of subjects: 0
Study 35524239 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 350 mg QD combined with Imatinib 400 mg QD
Number of subjects: 56
Study 35524363 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential Living Donors (PLDs) present
Number of subjects: 847